Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

RSS icon

TCT: OPTIMIZE supports 3-month DAPT in some patients

SAN FRANCISCO—Some patients implanted with a newer generation drug-eluting stent (DES) may safely discontinue dual antiplatelet therapy (DAPT) at three months, results from the OPTIMIZE trial presented Oct. 31 at the Transcatheter Cardiovascular Therapeutics (TCT) scientific session in San Francisco showed. 

TCT recap: TRYTON, EuroMax, CoreValve, TAVR with CoreValve

In case you missed it, here is our previous coverage from TCT.

TCT: ADVISE II offers adenosine-free approach to assess lesions

SAN FRANCISCO—Would interventional cardiologists be more amenable to incorporating tools for assessing coronary stenosis before performing PCI or CABG if they could ditch the use of vasodilator drugs? Results from the ADVISE II registry trial presented Oct. 30 at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco may nudge them in that direction.

TCT recap: SAFE PCI, CHAMPION PHOENIX & OPEN II

In case you missed it, here is our previous coverage from the conference.

Thumbnail

TCT: Giving bivalirudin in ambulance improves STEMI outcomes

SAN FRANCISCO—Research presented Oct. 30 at the Transcatheter Cardiovascular Therapeutics (TCT) scientific session in San Francisco showed that administering bivalirudin to STEMI patients in an ambulance reduces the risk of death and major bleeding complications compared to heparin. But don’t expect quick adoption of the strategy in the U.S.

TCT: TRYTON misses the mark but reasons under debate

SAN FRANCISCO—The pivotal TRYTON trial failed to meet its primary clinical endpoint, findings that underscore limitations with classical clinical trial criteria, the lead investigator and panelists suggested Oct. 30 at the Transcatheter Cardiovascular Therapeutics (TCT) scientific session in San Francisco.

OrbusNeich's COMBO(tm) Dual Therapy Stent shows excellent early healing and durable outcomes out to 24 months

OrbusNeich today announced that new clinical data presented at TCT 2013 show durable outcomes as well as excellent early healing and optimal neointimal suppression out to 24 months following placement of the COMBO Dual Therapy Stent. These results from the EGO-COMBO Study were presented by Stephen W.L. Lee, M.D., of the Queen Mary Hospital, University of Hong Kong, China, at the annual interventional cardiology conference in San Francisco.

Thumbnail

TCT: CoreValve quality of life gains parallel PARTNER

SAN FRANCISCO—Patients in the CoreValve Extreme Risk trial experienced a magnitude of improvement in quality of life similar to PARTNER B, David Cohen, MD, said Oct. 29 at the Transcatheter Cardiovascular Therapeutics (TCT) conference. For some, the procedure “reset the clock by 10 years.”

Displaying 7857 - 7864 of 10758

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.